Loading...
By Kristin J. Kelley
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
The FDA has approved an insulin glargine injection (marketed as Basaglar) for treating type 1 (adult and pediatric patients) and type 2 (adults) diabetes mellitus. The drug is similar enough to another man-made form of insulin — Lantus — to gain approval through an accelerated review process.
The once-daily subcutaneous injection should be dosed according to individual patient needs and must be given at the same time every day. The drug was shown to be safe and efficacious in two studies comprising nearly 1300 patients.
The injection shouldn't be used in patients who are hypoglycemic or have a hypersensitivity to insulin glargine. In trials, common side effects included allergic reactions, edema, hypoglycemia, itching, lipodystrophy, and weight gain. More serious adverse reactions can include anaphylaxis, angioedema, bronchospasm, hypotension, and shock.
Basaglar will be available in December of 2016, according to a Reuters report. It will be less expensive than Lantus.
Comment
LINK(S):
FDA news release (Free)
Washington Post story on the cost of diabetes drugs (Free)
Reuters story (Free)